Cargando…
Drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial
BACKGROUND: Drotaverine, a spasmolytic, has been found to have potential to achieve a reduction in the duration of labour and prevent prolonged labour. OBJECTIVE: To compare the effects of intravenous drotaverine hydrochloride with placebo for shortening the duration of active phase of labour in pri...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Makerere Medical School
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993253/ https://www.ncbi.nlm.nih.gov/pubmed/36910347 http://dx.doi.org/10.4314/ahs.v22i3.13 |
_version_ | 1784902492445736960 |
---|---|
author | Ikeotuonye, Arinze Chidiebele Umeora, Odidika Johannes Nwafor, Johnbosco Ifunanya Ojumah, Bonaventure Omuye Ekwunife, Ifeoma Cecilia Dimejesi, Ikechukwu Bonaventure |
author_facet | Ikeotuonye, Arinze Chidiebele Umeora, Odidika Johannes Nwafor, Johnbosco Ifunanya Ojumah, Bonaventure Omuye Ekwunife, Ifeoma Cecilia Dimejesi, Ikechukwu Bonaventure |
author_sort | Ikeotuonye, Arinze Chidiebele |
collection | PubMed |
description | BACKGROUND: Drotaverine, a spasmolytic, has been found to have potential to achieve a reduction in the duration of labour and prevent prolonged labour. OBJECTIVE: To compare the effects of intravenous drotaverine hydrochloride with placebo for shortening the duration of active phase of labour in primigravidas. METHODS: A double-blind, placebo-controlled randomized trial of 246 primigravidas in active phase of labour at term was conducted. They were randomly (1:1 ratio) administered intravenous 2 ml (40mg) of drotaverine hydrochloride or 2 ml of Vitamin B complex as placebo. The primary outcome measure was the duration of active phase of labour. The secondary outcome measures were cervical dilatation rate, oxytocin augmentation rate, incidence of prolonged labour, labour pain scores, mode of delivery, maternal and neonatal outcomes. RESULTS: The mean duration of active phase of labour (hour) was significantly lower in the drotaverine group compared to the control (drotaverine; 6.22 ± 2.41 vs placebo; 8.33 ± 3.56; p <0.001). Also, the cervical dilatation rate (cm/hr) was significantly faster in the drotaverine arm (drotaverine; 1.68 ± 1.02 versus placebo; 1.06 ± 0.53, p <0.001). There was a significantly higher probability of faster delivery among women who were given drotaverine (log-rank test, p < 0.001). The oxytocin augmentation rate, incidence of prolonged labour, labour pain scores, mode of delivery, maternal and neonatal outcomes were not significantly different among the groups. CONCLUSIONS: Drotaverine hydrochloride is effective in shortening the duration of active phase of labour without adverse maternal and neonatal outcomes. However, more evidence is needed to explore its role in active phase of labour among primigravid women. Trial registration number: PACTR201810902005232. |
format | Online Article Text |
id | pubmed-9993253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Makerere Medical School |
record_format | MEDLINE/PubMed |
spelling | pubmed-99932532023-03-09 Drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial Ikeotuonye, Arinze Chidiebele Umeora, Odidika Johannes Nwafor, Johnbosco Ifunanya Ojumah, Bonaventure Omuye Ekwunife, Ifeoma Cecilia Dimejesi, Ikechukwu Bonaventure Afr Health Sci Articles BACKGROUND: Drotaverine, a spasmolytic, has been found to have potential to achieve a reduction in the duration of labour and prevent prolonged labour. OBJECTIVE: To compare the effects of intravenous drotaverine hydrochloride with placebo for shortening the duration of active phase of labour in primigravidas. METHODS: A double-blind, placebo-controlled randomized trial of 246 primigravidas in active phase of labour at term was conducted. They were randomly (1:1 ratio) administered intravenous 2 ml (40mg) of drotaverine hydrochloride or 2 ml of Vitamin B complex as placebo. The primary outcome measure was the duration of active phase of labour. The secondary outcome measures were cervical dilatation rate, oxytocin augmentation rate, incidence of prolonged labour, labour pain scores, mode of delivery, maternal and neonatal outcomes. RESULTS: The mean duration of active phase of labour (hour) was significantly lower in the drotaverine group compared to the control (drotaverine; 6.22 ± 2.41 vs placebo; 8.33 ± 3.56; p <0.001). Also, the cervical dilatation rate (cm/hr) was significantly faster in the drotaverine arm (drotaverine; 1.68 ± 1.02 versus placebo; 1.06 ± 0.53, p <0.001). There was a significantly higher probability of faster delivery among women who were given drotaverine (log-rank test, p < 0.001). The oxytocin augmentation rate, incidence of prolonged labour, labour pain scores, mode of delivery, maternal and neonatal outcomes were not significantly different among the groups. CONCLUSIONS: Drotaverine hydrochloride is effective in shortening the duration of active phase of labour without adverse maternal and neonatal outcomes. However, more evidence is needed to explore its role in active phase of labour among primigravid women. Trial registration number: PACTR201810902005232. Makerere Medical School 2022-09 /pmc/articles/PMC9993253/ /pubmed/36910347 http://dx.doi.org/10.4314/ahs.v22i3.13 Text en © 2022 Ikeotuonye AC et al. https://creativecommons.org/licenses/by/4.0/Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Ikeotuonye, Arinze Chidiebele Umeora, Odidika Johannes Nwafor, Johnbosco Ifunanya Ojumah, Bonaventure Omuye Ekwunife, Ifeoma Cecilia Dimejesi, Ikechukwu Bonaventure Drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial |
title | Drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial |
title_full | Drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial |
title_fullStr | Drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial |
title_full_unstemmed | Drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial |
title_short | Drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial |
title_sort | drotaverine to shorten the duration of labour in primigravidas: a randomised, double-blind, placebo-controlled trial |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993253/ https://www.ncbi.nlm.nih.gov/pubmed/36910347 http://dx.doi.org/10.4314/ahs.v22i3.13 |
work_keys_str_mv | AT ikeotuonyearinzechidiebele drotaverinetoshortenthedurationoflabourinprimigravidasarandomiseddoubleblindplacebocontrolledtrial AT umeoraodidikajohannes drotaverinetoshortenthedurationoflabourinprimigravidasarandomiseddoubleblindplacebocontrolledtrial AT nwaforjohnboscoifunanya drotaverinetoshortenthedurationoflabourinprimigravidasarandomiseddoubleblindplacebocontrolledtrial AT ojumahbonaventureomuye drotaverinetoshortenthedurationoflabourinprimigravidasarandomiseddoubleblindplacebocontrolledtrial AT ekwunifeifeomacecilia drotaverinetoshortenthedurationoflabourinprimigravidasarandomiseddoubleblindplacebocontrolledtrial AT dimejesiikechukwubonaventure drotaverinetoshortenthedurationoflabourinprimigravidasarandomiseddoubleblindplacebocontrolledtrial |